Tag Archives: Moderna

United Airlines (UAL) Shares of the airline are up more than 5% in after hours after better-than-expected quarterly results and earnings guidance. United sees its first quarter adjusted earnings anywhere between 50 cents and $1.00, beating estimates of 22 cents per share. The airline reported fourth quarter EPS of $2.36 versus analysts’ consensus expectations of of $2.12. It’s revenue of $12.4 billion also came in above expectations of $12.2 billion. The airline said it able to recover quickly… Source link

The majority of Moderna’s (MNRA) revenue comes from governments abroad — which are bracing are for an ongoing need for COVID-19 vaccines this year. While the U.S. waits on funding and for the U.S. Food and Drug Administration (FDA) to decide on which virus strain to attack through boosters, Moderna and other vaccine companies are anticipating waning immunity to become a concern. “This virus is not getting less infectious,” Moderna CEO Stéphane Bancel told Yahoo Finance. “As you see more and… Source link

Moderna (MRNA) filed a request for emergency use authorization (EAU) for its COVID-19 vaccine for use in kids between 6 months and under 6 years Thursday. The request is for the approval of two doses of 25 micrograms of the mRNA vaccine. Moderna’s clinical data showed the vaccine was 51% effective for the older cohort of the age group, from 2 years to under six years, and 37% effective for the younger group. The company said this is about the same as adult vaccine efficacy of two doses against… Source link

The reaction to a potential COVID-19 vaccine breakthrough for young children out of Moderna (MRNA) may have some traders scratching their heads. Shares of the biotech fell 3% on Wednesday on positive interim data released by Moderna for its coronavirus vaccine for children under six years old. Moderna said the shots were about 44% effective in preventing Omicron in children six months up to two years old. “We believe these latest results from the KidCOVE study are good news for parents of… Source link

Whether or not people will need to be perpetually boosting against the coronavirus and its seemingly never-ending stream of variants remains unknown, but vaccine manufacturers are already preparing for a possible need for additional boosters in the fall. “We have to be prepared for whatever evolution gives us,” said Moderna (MRNA) CEO Stéphane Bancel. Bancel, as well as Pfizer (PFE) CEO Albert Bourla, spoke to Yahoo Finance during the annual JPMorgan Health Care conference Monday. Both… Source link

By Lewis Krauskopf and Manojna Maddipatla (Reuters) – Positive clinical trial results for Merck & Co’s experimental antiviral COVID-19 pill reverberated through the healthcare sector on Friday, sending the drugmaker’s stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies. Merck shares jumped as much as 12.3% and hit their highest level since February 2020 after data showed the company’s pill molnupiravir… Source link

With the White House aiming for a Sept. 20 start date for COVID-19 booster shots for adults in the U.S., the countdown has begun for the U.S. Food and Drug Administration (FDA) to review booster data from vaccine companies.  Moderna (MRNA), meanwhile, is focused on halving its booster shot, from the current 100 microgram dose. The company submitted to the FDA an initial round of data to support the half dose this week. According to Moderna officials, the lower dosage has production benefits… Source link

Heading into a new trading week, Pfizer Inc. (NYSE: PFE), Alibaba Group Holding Limited (NYSE: BABA), Nvidia Corp. (NASDAQ: NVDA) and Moderna Inc. (NASDAQ: MRNA) are among the stocks seeing the highest interest on Reddit’s r/WallStreetBets forum. What Happened: Pfizer has emerged as the most-discussed stock on the forum with 106 mentions, followed by exchange-traded fund SPDR S&P 500 ETF Trust (NYSE: SPY) with 102 mentions, data from Quiver Quantitative showed. Chinese e-commerce giant… Source link

mRNA-3705 is Moderna’s second rare disease program to enter clinical studies mRNA-3705 granted Orphan Drug and Rare Pediatric Disease designation by the U.S. FDA MMA associated with significant mortality and morbidity; there are no approved therapies CAMBRIDGE, Mass., August 16, 2021–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first patient has been enrolled in the Phase… Source link

This weekend’s Barron’s cover story takes a close look at what it will take to fix Boeing. Other featured articles discuss reliable growth stocks, whether inflation is different this time and who has the early lead in the metaverse. Also, see the prospects for a COVID-19 vaccine maker, a real estate investment trust, a video game leader, a fast-food chain and more. “Boeing’s Fix-It Job: How the Company Can Win the Future” by Al Root explores why shares in Boeing Co (NYSE: BA), the world’s… Source link